GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Monte Rosa Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.66+0.92 (+9.45%)
Close on Oct 19, 2026
- Market cap
- $1.08B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.61 (+6.07%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Monte Rosa Therapeutics, Inc. saw revenue fall 83.9% to $28.73M over the twelve months to Jun 30, 2026. Operating income fell 1315.7% to -$181.85M, moving the operating margin from 8.4% to -633.0%. Free cash flow was -$32.08M, down 234.5% from a year earlier.
Revenue
$28.73M
-83.9% vs. a year earlier
Operating income
-$181.85M
-1315.7% vs. a year earlier
Free cash flow
-$32.08M
-234.5% vs. a year earlier
EPS, diluted
-$1.76
-706.9% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.08B
- P/E ratio
- –
- Price to sales
- 37.66
- Price to book
- 2.22
- Dividend yield
- –
- Free cash flow yield
- -2.97%
Fundamentals
- Revenue
- $28.73M
- Net income
- -$161.09M
- EPS, diluted
- -$1.76
- Free cash flow
- -$32.08M
- Book value per share
- $4.80
- Diluted shares
- 101M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$28.73M-83.9% YoY
Operating income
-$181.85M-1315.7% YoY
Net income
-$161.09M-766.5% YoY
EPS, diluted
-$1.76-706.9% YoY
Free cash flow
-$32.08M-234.5% YoY
Reported periodTrailing twelve months